9 completed, 2 terminated, 1 no longer available. 7 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow ERYtech Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Eryaspase, FOLFIRINOX - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Georgetown University | 19 | 2020-12-02 | 2025-06-11 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) eryaspase (L-asparaginase encapsulated in red blood cells), Gemcitabine, Carboplatin - Triple Negative Breast Cancer | Phase 2 / Phase 3 | Terminated | ERYtech Pharma | 27 | 2019-06-13 | 2022-08-01 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin - Pancreatic Adenocarcinoma | Phase 3 | Completed | ERYtech Pharma | 512 | 2018-09-15 | 2022-10-18 |
| Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase GRASPA - Acute Lymphoblastic Leukemia | Phase 2 | Completed | Birgitte Klug Albertsen | 55 | 2017-08-23 | 2024-03-15 |
| Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma ERY001, Gemcitabine, 5-fluoro-uracil/oxaliplatin/leucovorin (folfox) - Pancreatic Adenocarcinoma Metastatic | Phase 2 | Completed | ERYtech Pharma | 141 | 2014-07-01 | 2018-07-27 |
| L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL L-asparaginase encapsulated in RBC - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Terminated | ERYtech Pharma | 14 | 2013-10-01 | 2018-07-05 |
| GRASPA Treatment for Patients With Acute Myeloblastic Leukemia GRASPA - Acute Myeloid Leukemia | Phase 2 | Completed | ERYtech Pharma | 123 | 2013-02-01 | 2022-02-21 |
| GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia GRASPA, L-asparaginase - Acute Lymphoblastic Leukemia, in Relapse | Phase 2 / Phase 3 | Completed | ERYtech Pharma | 85 | 2009-12-01 | 2022-02-02 |
| Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer GRASPA - Pancreatic Cancer | Phase 1 | Completed | ERYtech Pharma | 12 | 2009-11-01 | 2021-10-15 |
| Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia GRASPA - Acute Lymphoblastic Leukemia | Phase 2 | Completed | ERYtech Pharma | 30 | 2009-04-01 | 2021-10-15 |
| Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia GRASPA, native L asparaginase - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | ERYtech Pharma | 25 | 2006-01-01 | 2012-01-11 |
| Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase suspension of erythrocytes encapsulating L-asparaginase - Acute Lymphoblastic Leukemia | No longer available | ERYtech Pharma | 2018-12-04 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia (2) · Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
eryaspase (7) · Erythrocyte Count (3) · Gemcitabine (3) · Asparaginase (2) · Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Folfox protocol (1) · Oxaliplatin (1) · Paclitaxel (1) · folfirinox (1) · irinotecan sucrosofate (1)
France (6) · United States (3) · Belgium (2) · Denmark (1) · Estonia (1) · Finland (1) · Hungary (1) · Lithuania (1) · Norway (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Brigitte Klug Albertsen, MD, PhD (1) · Manuel Hidalgo, MD, PhD (1) · Marcus S Noel, MD (1) · Mathilde Hunault-Berger, Professor (1) · Pascal Hammel, MD, PhD (1) · Pascal Hammel, Pr MD (1) · X Thomas, Doctor (1) · Yves Bertand, MD (1) · Yves Bertrand, MD PhD (1)
PMID 26094614, PMID 26355551, PMID 31760314, PMID 32605910, PMID 41187298
2016 (1)